Inclusion Criteria:~* Previous participation in Study BN29552 or BN29553 and completion of the Week 105
visit.~* Able to provide written informed consent by the patient or legally authorized representative, if
required.~* Every effort to have the same caregiver participate throughout the duration of the OLE (Open Label
Extension) study who also participated in Study BN29552 or BN29553.~* Willingness and ability to complete all
aspects of the study \[including MRI (Magnetic Resonance Imaging), lumbar puncture \[if applicable\], and PET
(Positron Emission Tomography) imaging \[if applicable\].~* Adequate visual and auditory acuity, in the
investigator's judgment, sufficient to perform the neuropsychological testing.~* For women of childbearing
potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a protocol approved
contraceptive method and agreement to refrain from donating eggs for at least 8 weeks after last dose.~* For
men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a protocol approved
contraceptive method for at least 8 weeks after last dose.~
